Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-10-24
2009-02-24
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S385000
Reexamination Certificate
active
07494974
ABSTRACT:
The present invention includes compositions containing carboxymethylated cross-linked hemoglobin where the cysteine moiety of the hemoglobin includes thiol protecting group and where the hemoglobin is incapable of binding with the nitric oxide. Preferably, the hemoglobin is deoxygenated, endotoxin free, and stroma free. The present invention also includes method of preparation, process of preparation and the method of supplementing blood in mammals.
REFERENCES:
patent: 4473494 (1984-09-01), Tye
patent: 4529719 (1985-07-01), Tye
patent: 4650786 (1987-03-01), Wong
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4727027 (1988-02-01), Wiesehahn et al.
patent: 5028588 (1991-07-01), Hoffman et al.
patent: 5084558 (1992-01-01), Rausch et al.
patent: 5189146 (1993-02-01), Hsia
patent: 5234903 (1993-08-01), Nho et al.
patent: 5281579 (1994-01-01), Estep
patent: 5290919 (1994-03-01), Bucci et al.
patent: 5352773 (1994-10-01), Kandler et al.
patent: 5380824 (1995-01-01), Marschall et al.
patent: 5386014 (1995-01-01), Nho et al.
patent: 5532352 (1996-07-01), Pliura et al.
patent: 5563047 (1996-10-01), Petersen
patent: 5599907 (1997-02-01), Anderson et al.
patent: 5627266 (1997-05-01), Wainwright et al.
patent: 5733869 (1998-03-01), Burhop et al.
patent: 5747663 (1998-05-01), Colpan et al.
patent: 5750132 (1998-05-01), Gerber
patent: 5753616 (1998-05-01), Rausch et al.
patent: 5776890 (1998-07-01), Hoffman et al.
patent: 5789376 (1998-08-01), Hsia
patent: 5811005 (1998-09-01), Hsia
patent: 5840701 (1998-11-01), Hsia
patent: 5844090 (1998-12-01), Anderson et al.
patent: 5929031 (1999-07-01), Kerwin et al.
patent: 6894150 (2005-05-01), Tye
patent: 7019117 (2006-03-01), Acharya et al.
patent: 2008/0096805 (2008-04-01), Tye
patent: WO 90/13645 (1990-11-01), None
patent: WO 92/02239 (1992-02-01), None
patent: WO 92/08478 (1992-05-01), None
patent: WO 92/11283 (1992-07-01), None
patent: WO 92/22646 (1992-12-01), None
patent: WO 94/26286 (1994-11-01), None
Cheng et al. 2002; Ligand binding properties and structural studies or recombinant and chemically modified hemoglobins altered at b93 cysteine. Biochemistry 41: 11901-11913.
DiDonato et al. 1983; Selective carboxymethylation of the a-amino groups of hemoglobin. J. Biological Chemistry 258(10): 11890-11895.
Guidotti 1965; The rates reaction of the sulfhydryl groups of human hemoglobin. J. Biological Chemistry 240(10): 3924-3927.
Fantl et al. 1987; Properties of carboxymethylated corss-linked hemoglobin A. Biochemistry 26:5755-5761.
Taylor et al. 1966; Studies on human hemoglobin treated with various sulfhydryl reagents. J. Biological Chemistry 241(1): 241-248.
Manning 1981; Preparation of hemoglobin carbamylated at specific NH2-terminal residues. Methods in Enzymology 76: 159-167.
Manning et al. 1988; Influence of ligation state and concentration of hemoglobin A on its cross-linking by glycoaldehyde: Functional properties of cross-linked, carboxymethylated hemoglobin. Biochemistry 27: 6640-6644.
Allison, et al. The bioassay of human endogenous pyrogen. Clin Sci Mol Med. 1973; 45(4):449-58.
Benesch, et al. Affinity labeling of the polyphosphate binding site of hemoglobin, Biochemistry, 1972; 11(19):3576-82.
Benesch, et al. Hemoglobin covalently bridged across the polyphoshate binding site. Biochem Biophys Res Commun. 1975; 63(4):1123-9.
Benesch, et al. Labeling of hemoglobin with pyridoxal phosphate. J. Biol. Chem. 1982; 257(3):1320-1324.
Benesch, et al. Preparation and properties of hemoglobin modified with derivatives of pyridoxal. Methods Enzymol. 1981; 76:147-59.
Bleeker, et al. Endotoxin in blood products: correlation between the Limulus assay and the rabbit pyrogen test. Prog. Clin Biol Res. 1985;189:293-303.
Chan, et al. Slow Phase hemolysis in hypotonic electrolyte solutions. J. Cell Physiol. 1975; 85(1):47-57.
Dietz, et al. The effects of cross linked hemoglobin on regional vascular conductance in dogs, Anesth Analg 1997; 85: 265-273.
Dolman, et al. Membrane-covered thin-layer optical cell for gas-reaction studies of hemoglobin. Anal Biochem. 1978; 87(1):127-34.
Eperon, et al. Human monocytoid cell lines as indicators of endotoxin: comparison with rabbit pyrogen and Limulus amoebocyte lysate assay. J. Immunol Methods. 1997; 207(2):135-45.
Faivre-Fiorina, et al. Presence of hemoglobin inside aortic endothelial cells after cell-free hemoglobin administration guinea pig. Am J. Physiol Heart Circ Physiol 1999; 276: H766-H770.
Friedman, et al. Morphologic effects following massive exchange transfusion with a stroma-free hemoglobin solution, I Liver. Lab Invest. 1978; 39(2):167-77.
Fujiwara, et al. Measurement of endotoxin in blood products using an endotoxin-specific Limulus test reagent and its relation to pyrogenic activities in rabbit. Yakugaku Zasshi. 1990; 110(5):332-40. (in Japanese with English abstract).
Gulati et al. Effect of diaspirin crosslinked and stroma-reduced hemoglobin on mean arterial pressure and endothelin-1 concentration in rats. Life. Sci 1995; 56:1433-1442.
Gulati et al. Role of adrenergic mechanisms in the pressor effect of diaspirin cross-linked hemoglobin. J Lab Clin Med 1994; 124: 125-33. (Abstract only. 1 page.).
Gulati, et al. Role of endothelin in the cardiovascular effects of diaspirin crosslinked and stroma reduced hemoglobin. Crit. Care Med 1996; 24: 137-47. (21 pages).
Hale, A. S. Canine blood groups and their importance in veterinary transfusion medicine. Vet Clin North Am Small Anim Pract. 1995; 25(6):1323-32.
Harrell, et al. Canine transfusion reactions their management. Vet Clin North Am Small Anim Pract. 1995; 25(6):1333-64.
Intaglietta, et al. Microvascular and tissue oxygen distribution. Cardiovasc Res 1996; 32: 632-43.
Jia, et al. S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control, Nature. 1996; 380(6571):221-6.
Kasper, et al. Effects of a hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth Analg 1996; 83:921-7.
Kasper, et al. The Effect of increased doses of bovine hemoglobin on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth Analg 1998; 87:284-91.
Katsuyama, et al. Nitric oxide mediates the hypertensive response to a modified hemoglobin solution (DCLHb) in rats. Artif Cells Blood Substit Immobil Biotechnol. 1994: 22(1):1-7.
Lawn, et al. The nucleotide sequence of the human beta-globin gene. Cell. 1980; 21(3):647-51.
Levy, et al. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J Thorac Cardiovasc Surg 2002; 124: 35-42.
Liebhaber, et al. Cloning and complete uncleotide sequence of human 5′-alpha-globin gene. Proc Natl Acad Sci U S A. 1980; 77(12):7054-8.
MacDonald, et al. Coronary vasoconstrictor activity of purified and modified human hemoglobin. Biomater Artif Cells Artif Organs 1990; 18: 263-282.
Marotta, et al. Human beta-globin messenger RNA. III. Nucleotide sequences derived from complementary DNA. J Biol Chem. 1977: 252(14):5040-53.
Martel, et al. Limulus test using a chromogenic method: application to the control of pyrogens in blood derivatives. Rev Fr Transfus Immunohematol. 1985; 28(3):237-50. (in French with English summary).
McCarthy, et al. The role of facilitated diffusion in oxygen transport by cell-free hemoglobins: implications for the design of hemoglobin-based oxygen carriers. Biophys Chem 2001; 92: 103-17. (Abstract only. 1 page).
Pool, et al. The detection of pyrogens in blood products using an ex vivo whole blood culture assay. J Immunoassay. 1998; 19(2-3):95-111.
Poole, et al. Assay of pyrogenic contamination in pharmaceuticals by cytokine release from monocytes. Dev Biol Stand. 1988; 69:121-3.
Rabiner, et al. Evaluation of a stroma-free hemoglobin solution for use as a plasma expander. J Exp. Med. 1967; 126(6):1127-42.
Sakai, et al. Microvascular responses to hemodilution with Hb vesicles as red blood cell substitutes:
Carlson Karen Cochrane
Halluin Albert P.
IKOR, Inc.
Radel Peggy A.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Carboxymethylated cross-linked tetrameric hemoglobin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carboxymethylated cross-linked tetrameric hemoglobin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carboxymethylated cross-linked tetrameric hemoglobin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4064607